Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint
Phase III clinical study (Study Protocol No.: KN026-003) of Anbenitamab (‘‘KN026’’), co-developed by Shanghai JMT-BIO Technology Co., Ltd. (‘‘JMT-BIO’’), a subsidiary of the Company, and Jiangsu Alphamab Oncology Co., Ltd., in combination with the Group’s self-developed Docetaxel for Injection (Albumin-bound) (‘‘HB1801’’) for the first-line treatment of HER2-positive advanced breast cancer has successfully met the pre-specified primary endpoint of progression-free survival (‘‘PFS’’) as assessed by the Independent Data Monitoring Committee (the ‘‘IDMC’’), yielding results that are both statistically significant and clinically meaningful, with a favourable safety profile.
Share:
More News
“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as
“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the